



Biflavonoids from *Torreya nucifera* displaying SARS-CoV 3CL^{pro} inhibition

Young Bae Ryu^{a,†}, Hyung Jae Jeong^{a,†}, Jang Hoon Kim^a, Young Min Kim^a, Ji-Young Park^a, Doman Kim^b, Thi Thanh Hanh Nguyen^b, Su-Jin Park^a, Jong Sun Chang^a, Ki Hun Park^c, Mun-Chual Rho^{a,*}, Woo Song Lee^{a,*}

^a Eco-Friendly Biomaterial Research Center and AI Control Material Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongseup 580-185, Republic of Korea

^b School of Biological Science and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea

^c Division of Applied Life Science (BK 21 Program), EB-NCRC, Institute of Agriculture and Life Science, Graduate School of Gyeongsang National University, Jinju 660-701, Republic of Korea

ARTICLE INFO

Article history:

Received 10 August 2010

Revised 14 September 2010

Accepted 15 September 2010

Available online 19 September 2010

Keywords:

SARS-CoV 3CL^{pro}

Torreya nucifera

Biflavonoid

Amentoflavone

ABSTRACT

As part of our search for botanical sources of SARS-CoV 3CL^{pro} inhibitors, we selected *Torreya nucifera*, which is traditionally used as a medicinal plant in Asia. The ethanol extract of *T. nucifera* leaves exhibited good SARS-CoV 3CL^{pro} inhibitory activity (62% at 100 µg/mL). Following bioactivity-guided fractionation, eight diterpenoids (**1–8**) and four biflavonoids (**9–12**) were isolated and evaluated for SARS-CoV 3CL^{pro} inhibition using fluorescence resonance energy transfer analysis. Of these compounds, the biflavone amentoflavone (**9**) (IC₅₀ = 8.3 µM) showed most potent 3CL^{pro} inhibitory effect. Three additional authentic flavones (apigenin, luteolin and quercetin) were tested to establish the basic structure–activity relationship of biflavones. Apigenin, luteolin, and quercetin inhibited 3CL^{pro} activity with IC₅₀ values of 280.8, 20.2, and 23.8 µM, respectively. Values of binding energy obtained in a molecular docking study supported the results of enzymatic assays. More potent activity appeared to be associated with the presence of an apigenin moiety at position C-3' of flavones, as biflavone had an effect on 3CL^{pro} inhibitory activity.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Severe acute respiratory syndrome (SARS), a contagious and often fatal respiratory illness, was first reported in Guangdong province, China, in November 2002.^{1,2} Its rapid and unexpected spread to other Asian countries, North America, and Europe alarmed both the public and the World Health Organization (WHO). SARS is caused by the novel coronavirus (CoV), SARS-CoV.^{3,4} SARS-CoV is a positive-strand RNA virus whose genome sequence exhibits only moderate homology to other known coronaviruses.⁵ SARS-CoV encodes a chymotrypsin-like protease (3CL^{pro}), which is also called the main protease (M^{pro}) because it plays a pivotal role in processing viral polyproteins and controlling replicase complex activity.⁶ This enzyme is indispensable for viral replication and infection processes, thereby making it an ideal target for the design of antiviral therapies. The 3CL active site contains a catalytic dyad in which a cysteine residue (Cys145) acts as a nucleophile and a histidine residue (His41) acts as the general acid–base.⁶ To date, SARS-CoV 3CL^{pro}

inhibitors have been reported from both synthetic peptidyl compound libraries and natural product derived libraries.⁷ Inhibitory synthetic compounds include C2-symmetric diols,⁸ quinolinecarboxylic acids,⁹ isatins,¹⁰ and anilides.¹¹ Natural-derived inhibitors include betulinic acid,¹² indigo,¹³ aloemodin,¹³ luteolin,⁷ and quinine-methide triterpenoids; the latter are products of our latest investigation 3CL^{pro} inhibitor from *Tripterygium regelii*.¹⁴ These natural molecules were found to have IC₅₀ values ranging from 3 to 300 µM in the enzyme assays.

As part of an ongoing investigation of potential SARS-CoV 3CL^{pro} inhibitors from medicinal plants, we performed an initial screen of ethanol extracts of the leaves of *Torreya nucifera* using a fluorescence resonance energy transfer (FRET) assay. *T. nucifera*, a Taxaceae tree found in snowy areas near the Sea of Jeju Island in Korea that has been used in traditional Asian medicine as a remedy for stomachache, hemorrhoids, and rheumatoid arthritis, was chosen as the starting material by virtue of its observed 3CL^{pro} inhibition (62% at 100 µg/mL). We isolated 12 phytochemicals—eight diterpenoids and four biflavonoids—with SARS-CoV 3CL^{pro} inhibitory activity from the ethanol extracts of the leaves of *T. nucifera*. All isolated compounds were examined for their 3CL^{pro} inhibitory activities by enzymatic inhibition assay. Of the isolated compounds, biflavonoid amentoflavone (**9**) was identified as a potent inhibitor of SARS-CoV 3CL^{pro}, exhibiting an IC₅₀ value of 8.3 µM. We also report on enzyme-inhibition mechanisms ascertained using kinetic plots and molecular docking experiments.

Abbreviations: SARS, severe acute respiratory syndrome; CoV, coronavirus; IC₅₀, concentration producing a 50% reducing in activity; K_i, inhibition constant; V_{max}, maximum velocity; K_m, Michaelis–Menten constant; RFUs, relative fluorescence units.

* Corresponding authors. Tel.: +82 63 570 5230 (M.-C.R.); tel.: +82 63 570 5170; fax: +82 63 570 5239 (W.S.L.).

E-mail addresses: rho-m@kribb.re.kr (M.-C. Rho), wslee@kribb.re.kr (W.S. Lee), wslee@kribb.re.kr (W.S. Lee).

[†] Both authors contributed equally to the work.

2. Results and discussion

2.1. Isolation and identification of SARS-CoV 3CL^{pro} inhibitory compounds

The crude ethanol extracts of the leaves of *T. nucifera* were directly analyzed by HPLC chromatography. As shown in Figure 1, more than 15 principal secondary metabolite peaks were detected in the chromatogram by photodiode array (PDA) at 210 nm. As a first step toward relating biological activity to principle metabolites, we assessed the SARS-CoV 3CL^{pro} inhibitory effects of the *T. nucifera* EtOH extract, along with *n*-hexane and EtOAc fractions. The results indicate that *n*-hexane (27% at 50 µg/mL, Fig. 1B) and EtOAc fractions (53% at 50 µg/mL, Fig. 1C) have good 3CL^{pro} inhibitory activity. We then used repeated open silica gel column, RP-18 gel, and Sephadex (LH-20) chromatography to isolate bioactive compounds from both fractions for further phytochemical

investigation. Their chemical structures were unambiguously assigned on the basis of a comprehensive spectral analysis of mass spectrometry and 1D, 2D NMR data, and a comparison to previously published data.^{15–23} Compounds isolated from the *n*-hexane fraction (1–8) were identified as the known diterpenoid species 18-hydroxyferruginol (1), hinokiol (2), ferruginol (3), 18-oxoferruginol (4), O-acetyl-18-hydroxyferruginol (5), methyl dehydroabietate (6), isopimaric acid (7), and kayadiol (8). The EtOAc fraction yielded four biflavonoids (9–12), which were identified as amentoflavone (9), bilobetin (10), ginkgetin (11), and sciadopitysin (12) (Fig. 2).

2.2. Effects of isolated compounds on the activity of SARS-CoV 3CL^{pro}

To investigate the relative inhibitory potency of the 12 compounds (1–12) against SARS-CoV 3CL^{pro}, we measured SARS-CoV




Figure 1. (A) HPLC total chromatogram of EtOH extract of *T. nucifera*. HPLC chromatograms of hexane (B) and EtOAc fraction (C) of *T. nucifera* leaves extract.




Figure 2. Chemical structures of isolated compounds (**1–12**) from leaves of the *T. nucifera*.

3CL^{pro} activity in the presence or absence of test compounds using fluorogenic methods. Unless otherwise stated, all compounds were first tested at a single maximum concentration of 300 μ M, after which IC₅₀ determinations were made using twofold serial dilutions starting from 300 μ M, following a previously described protocol. The 12 tested phytochemicals inhibited SARS-CoV 3CL^{pro} in a dose-dependent manner, as shown in Figure 3. The inhibitory effects of isolate compounds (**1–12**) on 3CL^{pro} activity, in vitro are summarized in Tables 1 and 2.

Table 1 displays the inhibitory activities of the eight in-house diterpenoid libraries against SARS-CoV 3CL^{pro}. The inhibitory potencies and capacities were not affected by subtle changes in structure. A recent study by Shyur and co-workers¹² showed that naturally occurring diterpenoid inhibit SARS-CoV 3CL^{pro} activity at concentrations of less than 100 μ M. In the present study, we found that these compounds also possessed similar inhibitory effects toward 3CL^{pro}, with over half of the tested compounds (**1**, **2**, and **4–8**) inhibiting SARS-CoV 3CL^{pro} at concentrations up to 100 μ M. One exception was ferruginol (**3**), which exhibited significantly greater inhibitory effects on 3CL^{pro} (IC₅₀ = 49.6 μ M) in our laboratory assay system than was found in this previous study.

Notably, ferruginol (**3**) was nearly a fourfold more potent inhibitor than the parent abietan diterpenoid, abietic acid (IC₅₀ = 189.1 μ M).

In separate experiments, we assessed the biflavonoid derivatives (**9–12**) for inhibition of SARS-CoV 3CL^{pro}. As shown in Table 2, we found that the IC₅₀ values of the biflavonoid derivatives **9–12** against SARS-CoV 3CL^{pro} ranged from 8.3 to 72.3 μ M. Of these compounds (**9–12**), amentoflavone (**9**) (IC₅₀ = 8.3 μ M) was the most potent SARS-CoV 3CL^{pro} inhibitor. To the best of our knowledge, this is the first report of the biological activity of biflavonoid derivatives toward SARS-CoV 3CL^{pro}.

2.3. Structural–activity relationships (SARs) of biflavones 9–12

We next performed a qualitative analysis of the structural–activity relationships of compounds **9–12**. A comparison of biflavone amentoflavone (**9**) with biflavone derivatives revealed that methylation of 7-, 4'-, and 4'''-hydroxyl groups diminished inhibitory activity, whereas a naked biflavone, as in amentoflavone (**9**), increased inhibitory activity. Thus, compounds **10–12**, which have methoxy groups, were less potent (IC₅₀ = 32.0–72.3 μ M) than compound **9**, which lacks a methoxy group. We also found that the




Figure 3. Effects of diterpenoids (**1–8**, A) and biflavones (**9–12**, B) on the activity of SARS-CoV 3CL^{pro}.

Table 1
SARS-CoV 3CL^{pro} inhibitory activities of isolated diterpenoids (**1–8**)

Compound	Inhibition ^a (%)	IC ₅₀ ^b (μM)
1	45.8 ± 5.0	220.8 ± 10.4
2	39.1 ± 11.6	233.4 ± 22.2
3	92.7 ± 3.7	49.6 ± 1.5
4	70.5 ± 1.3	163.2 ± 13.8
5	78.6 ± 8.8	128.9 ± 25.2
6	46.7 ± 7.2	207.0 ± 14.3
7	28.9 ± 2.2	283.5 ± 18.4
8	75.2 ± 5.4	137.7 ± 12.5
Abietic acid ^c	58.0 ± 4.8	189.1 ± 15.5

^a SARS-CoV 3CL^{pro} inhibition rate for compounds concentration at 200 μM.

^b All compounds were examined in a set of duplicated experiment; IC₅₀ values of compounds represent the concentration that caused 50% enzyme activity loss.

^c This compound was used as diterpenoid positive control.

location of the methoxy group within these compounds was positively correlated with the potency of the compounds against SARS-CoV 3CL^{pro}. The terminal methoxy groups in C-4' and -4'' were not required for 3CL^{pro} inhibition, as shown by compounds **10** and **12**, which exhibited moderated potency against 3CL^{pro}. However, substitution of a methoxy group at C-7 appeared to enhance the potency of the compound. For example, the C-7 methoxy group of compounds **11** (IC₅₀ = 32.0 μM) and **12** (IC₅₀ = 38.4 μM) might be responsible for twofold increase in the SARS-CoV 3CL^{pro} inhibitory activity relative to compound **10** (IC₅₀ = 72.3 μM). The rank order of potency of these derivatives was compound **9** (8.3 μM) > compound **11** (32.0 μM) > compound **12** (38.4 μM) > compound **10** (72.3 μM).

Table 2

SARS-CoV 3CL^{pro} inhibitory activities of isolated biflavonoids (**9–12**) and commercial flavonoids

Compound	IC ₅₀ ^a (μM)	Inhibition type (K _i , μM)
9	8.3 ± 1.2	Noncompetitive (13.8 ± 1.5)
10	72.3 ± 4.5	Noncompetitive (80.4 ± 4.0)
11	32.0 ± 1.7	Noncompetitive (30.2 ± 2.6)
12	38.4 ± 0.2	Noncompetitive (35.6 ± 1.1)
Apigenin ^b	280.8 ± 21.4	ND ^c
Luteolin ^b	20.0 ± 2.2	ND
Quercetin ^b	23.8 ± 1.9	ND

^a All compounds were examined in a set of triplicate experiment; IC₅₀ values of compounds represent the concentration that caused 50% enzyme activity loss.

^b These compounds were used to SAR study and positive control for biflavonoids.

^c ND = not determined.

To investigate the 3CL^{pro}-inhibitory profile of biflavones in detail and to elucidate their structure–activity relationships, we accessed a series of authentic flavones (apigenin, luteolin and quercetin) (Fig. 4). The most potent inhibitor (**9**) exhibited an IC₅₀ value toward SARS-CoV 3CL^{pro} of 8.3 μM, making this compound about 30-fold more potent than the parent compound apigenin, which had a threshold value of 40% at 200 μM in this experiment (Table 2). Moreover, this activity was higher than that of another flavone, luteolin (IC₅₀ = 20.2 μM). In the case of flavones, flavones with a C-3'-substituted hydroxyl group, as in luteolin, were more potent inhibitors than apigenin. Thus, these data suggested that substitution of the apigenin motif within the flavone as in biflavonoid (**9**) may play a pivotal role in SARS-CoV 3CL^{pro} inhibition. This relationship was also supported by quercetin (IC₅₀ = 23.8 μM), which has a hydroxyl group at the C-3' position in the flavones (Fig. 4).

2.4. Mechanistic analysis and molecular docking experiment

We also characterized the inhibitory mechanism of the isolated biflavonoids against SARS-CoV 3CL^{pro} activity. A representative example is illustrated in Figure 5, which shows the inhibition of SARS-CoV 3CL^{pro} by the most effective compound, amentoflavone (**9**). The enzyme inhibition mechanisms of biflavonoids were modeled using double-reciprocal plots (Lineweaver-Burk and Dixon plots). As shown in Figure 5A, the Dixon plot of [I] versus 1/V (RFU/min⁻¹) results in a family of straight lines with the same x-axis intercept, as illustrated for the three fluorogenic substrate concentrations [S], 1/2[S], and 1/4[S], respectively. This indicates that biflavonoids (**9–12**) exhibit noncompetitive inhibition characteristics toward 3CL^{pro} because V_{max} decreased without a change in K_m value in the presence of increasing concentrations of inhibitors (Fig. 5B). The K_i values of these biflavonoids were easily calculated from Dixon plot with a common intercept on the x-axis (corresponding to -K_i).

To further elucidate the interaction of SARS-CoV 3CL^{pro} with biflavone **9**, we employed in silico docking simulation. The three-dimensional structure of SARS-CoV 3CL^{pro} in complex with a substrate-analogue inhibitor (coded 2z3e)²⁴ obtained from the Protein Data Bank (PDB; <http://www.rcsb.org/pdb/>) was used for modeling analysis. Computer docking analysis revealed that biflavone **9** nicely fits in the binding pocket of 3CL^{pro}. As shown in Figure 6, the C5 hydroxyl group of **9** formed two hydrogen bonds with the nitrogen atom of the imidazole group of His163 (3.154 Å) and OH of Leu141 (2.966 Å) which are belonging to S1 site of 3CL^{pro}. Additionally, the hydroxyl group in the B ring of **9** forms hydrogen bonds with Gln189 (3.033 Å) which is belonging to S2 site of 3CL^{pro}. Our studies of structure–activity relationships implicated interactions with Val186 (4.228 Å) and Gln192 (3.898 Å) as one of the key




Figure 4. Chemical structures of apigenin, luteolin, quercetin, and amentoflavone (**9**).




Figure 5. (A) Dixon plot for inhibition of amentoflavone (**9**) on 3CL^{PRO} for the proteolysis of substrate. In the presence of difference concentrations of substrate: 2.5 μM ($\blacktriangledown$), 5.0 μM ($\circ$), and 10.0 μM ($\bullet$). (B) The plot of V_{max} versus inhibitor concentrations for determining the inhibition type.

chemotypes in this inhibitor. Moreover, the potencies of the inhibitors amentoflavone (**9**) and apigenin correlated well with their binding energies: amentoflavone (**9**) = -11.42 kcal/mol ; apigenin = -7.79 kcal/mol . These differences in binding energy apparently

manifest as a 30-fold smaller IC_{50} value of amentoflavone (**9**) toward 3CL^{PRO} compared with apigenin. Thus, this docking experiment supports the inferences drawn from the enzymatic assay, revealing an important inhibitory action of biflavones on SARS-CoV 3CL^{PRO}.




Figure 6. The binding pose of amentoflavone (**9**) in SARS-CoV 3CL^{PRO}. Ribbon plot of **9** complexed to 3CL^{PRO} with hydrogen bonding.

3. Conclusion

In conclusion, our results confirm that amentoflavone (**9**), isolated from *T. nucifera*, is an effective inhibitor of SARS-CoV 3CL^{pro} and is more effective than the corresponding flavones (apigenin and luteolin) and biflavonoid derivatives containing various numbers of methoxy groups. To the best of our knowledge, this is the first report to describe the inhibitory effects of amentoflavone (**9**) against 3CL^{pro}. The IC₅₀ value of this inhibitor, although higher than those of peptide-derived 3CL^{pro} inhibitors, is nonetheless in the low micromolar range. Thus, we believe that this compound may be a good candidate for development as a natural therapeutic drug against SARS-CoV infection.

4. Materials and methods

4.1. General apparatus and chemicals

¹H and ¹³C NMR along with 2D NMR data were obtained on JNM-ECA 400, 500 and 600 (JEOL, Tokyo, Japan) spectrometer using CDCl₃, DMSO-*d*₆, acetone-*d*₆, and methanol-*d*₃ with tetramethylsilane (TMS) as an internal standard. Melting points were measured on a Thomas Scientific Capillary Melting Point Apparatus (Electronthermal 9300, UK), and are uncorrected. Optical rotation values were measured using a Perkin-Elmer 343 polarimeter and [α]_D-values are given in units of 10^{−1} deg cm² g^{−1}. Chromatographic separations employed thin-layer chromatography (TLC) (Merck, Darmstadt, Germany) using commercially available glass plate pre-coated with silica gel; products were visualized under UV light at 254 and 366 nm. Column chromatography was carried out using 230–400 mesh silica gel (Kieselgel 60, Merck, Germany). RP-18 (ODS-A, 12 nm, S-150 mM; YMC), and Sephadex LH-20 (Amersham Biosciences).

4.2. Plant material

The leaves of *Torreya nucifera* were collected at Jeju Island, Republic of Korea, in October 2003. A voucher specimen was deposited in the author's laboratory in the KRIBB (Korea Research Institute of Bioscience and Biotechnology).

4.3. Extraction and isolation

Dried leaves (1.8 kg) of *T. nucifera* were extracted three times (2.0 L each) with ethanol (EtOH) at room temperature for 4 days. The ethanol extracts (228 g) were suspended in H₂O, and the resulting aqueous layer was successively partitioned with *n*-hexane, ethyl acetate (EtOAc), and H₂O to yield a hexane fraction (98 g), an EtOAc fraction (69 g), and aqueous fraction (44 g). The hexane-soluble fraction was subjected to silica gel column chromatography, with elution using a stepwise gradient mixture of *n*-hexane/EtOAc (100:0→10:1), to yield eight fractions (HF1–8). Fraction HF4 (10.6 g) was loaded onto a silica gel column, and eluted with a mixture of *n*-hexane/EtOAc (80:0→10:1) as the mobile phase to yield six fractions (HF4A–4F). Fraction HF4B (1.2 g) was further fractionated using a silica gel column; elution with a mixture of *n*-hexane/EtOAc (80:0→10:1) yielded compounds **3** (40 mg) and **4** (70 mg). Fraction HF4C (2.0 g) was chromatographed on a column of RP C-18 (75C18-PREP), and eluted with 70% acetonitrile–H₂O, to yield compounds **1** (11 mg), **2** (20 mg), **6** (12 mg), **7** (34 mg), and **8** (43 mg). Fraction HF4C was further purified by silica gel chromatography and eluted with *n*-hexane/CH₂Cl₂ (80:20, v/v) to yield compound **5** (17 mg).

The EtOAc fraction of *T. nucifera* was subjected to column chromatography over a silica gel; eluting with a chloroform-to-acetone

gradient yielded nine fractions (EF1–9). Fraction EF2 (8.8 g) was chromatographed on a Sephadex LH-20 column and eluted with methanol to yield five sub-fractions (EF2A–2E). Sub-fraction EF2A (1.4 g) was purified by silica gel chromatography and eluted with *n*-hexane/EtOAc (60:0→1:1) to yield compound **12** (30 mg). Sephadex LH-20 column chromatography was used to isolate compound **9** (50 mg) from fraction EF2C (0.9 g) using identical solvent conditions. This sub-fraction was subsequently separated through chromatography on a preparative-HPLC to yield compounds **10** (12 mg) and **11** (18 mg).

4.3.1. 18-Hydroxyferruginol (1)

Colorless prisms; [α]_D²⁰ = +109.9 (c 0.1, CHCl₃); mp: 175–180 °C; ¹H NMR (600 MHz, CDCl₃) δ 0.86 (3H, s, H-19), 1.18 (3H, s, H-20), 1.21 (3H, d, H-16), 1.22 (3H, d, H-17), 1.36 (1H, m, H-1α), 1.42 (1H, m, H-3), 1.59 (1H, m, H-5), 1.64 (1H, m, H-6), 1.71 (1H, m, H-2), 2.16 (1H, m, H-1β), 2.80 (2H, m, H-7), 3.09 (1H, m, H-15), 3.21 (1H, d, *J* = 10.9 Hz, H-18α), 3.45 (1H, d, *J* = 11.0 Hz, H-18β), 6.61 (1H, s, H-11), 6.81 (1H, s, H-14); ¹³C NMR (150 MHz, CDCl₃) δ 17.6 (C-19, t), 18.8 (C-6, t), 19.2 (C-2, t), 22.7 (C-16, q), 22.9 (C-17, q), 25.4 (C-20, q), 27.0 (C-15, d), 29.6 (C-7, t), 35.2 (C-3, t), 37.5 (C-10, s), 38.0 (C-4, s), 38.6 (C-1, t), 44.0 (C-5, d), 72.4 (C-18, t), 111.1 (C-11, d), 126.8 (C-14, d), 127.3 (C-8, s), 131.7 (C-13, s), 148.5 (C-9, s), 150.9 (C-12, s).

4.3.2. Hinokiol (2)

Colorless crystal; [α]_D²⁰ = +8.9 (c 0.1, CHCl₃); mp: 218–222 °C; ¹H NMR (600 MHz, CDCl₃) δ 0.86 (3H, s, H-18), 1.04 (3H, s, H-19), 1.15 (3H, s, H-20), 1.20 (3H, d, H-16), 1.22 (3H, d, H-17), 1.28 (1H, dd, *J* = 11.7, 2.1 Hz, H-15), 1.51 (1H, ddd, *J* = 26.8, 13.1, 4.1 Hz, H-1α), 1.72 (1H, m, H-2α), 1.74 (1H, m, H-6α), 1.77 (1H, m, H-2β), 1.84 (1H, m, H-6β), 2.17 (1H, m, H-1β), 2.75 (1H, m, H-7α), 2.86 (1H, dd, *J* = 16.5, 5.5 Hz, H-7β), 3.08 (1H, m, H-15), 3.27 (1H, dd, *J* = 11.6, 4.8 Hz, H-3), 6.59 (1H, s, H-11), 6.81 (1H, s, H-14); ¹³C NMR (150 MHz, CDCl₃) δ 15.6 (C-18, q), 19.2 (C-6, t), 22.7 (C-16, q), 22.9 (C-17, q), 25.0 (C-20, q), 27.0 (C-15, d), 28.2 (C-20, q), 28.4 (C-2, t), 30.2 (C-7, t), 37.2 (C-1, t), 37.5 (C-10, s), 39.2 (C-4, s), 78.9 (C-3, d), 111.2 (C-11, d), 126.8 (C-14, d), 127.3 (C-8, s), 131.9 (C-13, s), 148.0 (C-9, s), 150.9 (C-12, s).

4.3.3. Ferruginol (3)

Colorless oil; [α]_D²⁰ = +1.9 (c 0.1, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 0.89 (3H, s, H-19), 0.91 (3H, s, H-18), 1.15 (3H, s, H-20), 1.80 (1H, m, H-3α), 1.21 (3H, d, H-16), 1.22 (3H, d, H-17), 1.29 (1H, dd, *J* = 12.4, 2.1 Hz, H-5), 1.36 (1H, m, H-1α), 1.42 (1H, m, H-3β), 1.56 (1H, m, H-2α), 1.64 (1H, m, H-6α), 1.71 (1H, m, H-2β), 1.83 (1H, m, H-6β), 2.14 (1H, m, H-1β), 2.78 (2H, m, H-7), 3.09 (1H, seq, H-15), 6.61 (1H, s, H-11), 6.81 (1H, s, H-14); ¹³C NMR (150 MHz, CDCl₃) δ 19.4 (C-2, t), 19.5 (C-6, t), 21.8 (C-19, q), 22.7 (C-16, q), 22.9 (C-17, q), 25.0 (C-20, q), 27.0 (C-15, d), 29.9 (C-7, t), 33.5 (C-18, q), 33.6 (C-10, s), 37.7 (C-4, s), 39.1 (C-1, t), 41.8 (C-3, t), 50.5 (C-5, d), 111.2 (C-11, d), 126.8 (C-14, d), 127.5 (C-8, s), 131.5 (C-13, s), 148.9 (C-9, s), 150.8 (C-12, s).

4.3.4. 18-Oxoferruginol (4)

Colorless prisms; [α]_D²⁰ = +0.9 (c 0.1, CHCl₃); mp: 120–125 °C; ¹H NMR (600 MHz, CDCl₃) δ 1.13 (3H, s, H-19), 1.20 (3H, s, H-20), 1.22 (6H, d, H-16, 17), 1.27 (1H, m, H-1α), 1.31 (1H, m, H-2α), 1.44 (2H, m, H-3), 1.76 (2H, m, H-6), 1.78 (1H, m, H-2β), 1.88 (1H, dd, *J* = 2.0, 12.4 Hz, H-5), 2.21 (1H, m, H-1β), 2.79 (2H, m, H-7), 3.10 (1H, m, H-15), 6.62 (1H, s, H-11), 6.82 (1H, s, H-14), 9.23 (COH); ¹³C NMR (150 MHz, CDCl₃) δ 14.2 (C-19, q), 17.9 (C-2, t), 21.7 (C-6, t), 22.7 (C-16, q), 22.9 (C-17, q), 25.2 (C-20, q), 26.9 (C-15, d), 29.2 (C-7, t), 32.1 (C-3, t), 36.4 (C-10, s), 38.0 (C-1, t), 42.9 (C-5, d), 50.1 (C-4, s), 111.0 (C-11, d), 126.9 (C-14, d), 127.1 (C-8, s), 132.2 (C-13, s), 147.3 (C-9, s), 151.1 (C-12, s), 206.6 (C-18, s).

4.3.5. O-Acetyl-18-hydroxyferruginol (5)

White powder; $[\alpha]_D^{20} = +11.9$ (c 0.1, CHCl₃); mp: 155–160 °C; ¹H NMR (600 MHz, CDCl₃) δ 0.86 (3H, s, H-19), 1.16 (3H, s, H-20), 1.18 (3H, d, H-17), 1.20 (3H, d, H-16), 1.31 (1H, dd, $J = 3.4$, 13.0 Hz, H-1 β), 1.37 (2H, m, H-3), 1.58 (1H, dd, $J = 2.0$, 12.3 Hz, H-5), 1.64 (2H, m, H-6), 1.73 (2H, m, H-2), 2.11 (1H, d, $J = 12.3$ Hz, H-1 α), 2.15 (3H, s, H-22), 2.77 (2H, m, H-7), 3.11 (1H, m, H-15), 3.20 (1H, d, $J = 11.0$ Hz, H-18 β), 3.45 (1H, d, $J = 10.9$ Hz, H-18 α), 6.61 (1H, s, H-11), 6.79 (1H, s, H-14); ¹³C NMR (150 MHz, CDCl₃) δ 17.5 (C-19, q), 18.8 (C-2, t), 19.1 (C-6, q), 22.7 (C-16, q), 22.9 (C-17, q), 25.3 (C-20, q), 26.8 (C-15, d), 29.5 (C-7, t), 31.1 (C-22, q), 35.2 (C-3, t), 37.4 (C-4, s), 37.9 (C-10, s), 38.5 (C-1, t), 43.9 (C-5, d), 72.3 (C-18, t), 111.1 (C-11, d), 126.7 (C-14, d), 127.0 (C-13, s), 131.8 (C-8, s), 148.3 (C-9, s), 151.0 (C-12, s), 207.7 (C-21, s).

4.3.6. Methyl dehydroabietate (6)

Colorless oil; $[\alpha]_D^{20} = -0.9$ (c 0.1, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 1.18 (3H, s, H-20), 1.19 (6H, d, H-16, 17), 1.20 (3H, s, H-19), 1.13–1.50 (2H, m, H-6), 1.59–1.74 (2H, m, H-1), 1.66–1.83 (2H, m, H-2), 1.83–2.28 (2H, m, H-3), 2.22 (1H, dd, $J = 2.8$, 13.1 Hz, H-5), 2.80 (1H, m, H-15), 2.86 (2H, m, H-2), 3.64 (3H, s, H-18OMe), 6.86 (1H, s, H-14), 6.98 (1H, d, $J = 1.3$ Hz, H-12), 7.14 (1H, d, $J = 1.2$ Hz, H-11); ¹³C NMR (150 MHz, CDCl₃) δ 16.7 (C-19, q), 18.7 (C-2, t), 21.9 (C-6, t), 24.2 (C-16, -17, q), 25.3 (C-20, q), 30.2 (C-7, t), 33.6 (C-15, d), 36.8 (C-3, t), 37.1 (C-10, s), 38.1 (C-1, t), 45.0 (C-5, d), 47.8 (C-4, s), 52.1 (C-18OMe, s), 124.1 (C-11, d), 124.3 (C-12, d), 127.0 (C-14, d), 134.9 (C-8, s), 145.9 (C-13, s), 147.1 (C-9, s), 179.3 (C-18, s).

4.3.7. Isopimaric acid (7)

Colorless prisms; $[\alpha]_D^{20} = -0.9$ (c 0.1, CHCl₃); mp: 150–160 °C; ¹H NMR (600 MHz, CDCl₃) δ 0.86 (3H, s, H-19), 0.88 (3H, s, H-20), 1.12 (1H, m), 1.24 (3H, s, H-17), 1.36 (2H, m), 1.54 (3H, m), 1.63–2.00 (9H, m), 4.84 (1H, dd like, $J = 12.9$ Hz, H-16 β), 4.91 (1H, dd, $J = 1.5$, 21.2 Hz, H-16 α), 5.30 (1H, d like, H-17), 5.78 (1H, dd, $J = 12.8$, 21.2 Hz, H-15); ¹³C NMR (150 MHz, CDCl₃) δ 15.5 (C-20, q), 17.3 (C-19, q), 18.1 (C-2, t), 20.2 (C-11, t), 21.7 (C-17, q), 25.4 (C-6, t), 35.2 (C-10, s), 36.3 (C-12, t), 37.0 (C-3, t), 37.2 (C-13, s), 39.0 (C-1, t), 45.2 (C-5, d), 46.3 (C-4, s), 46.5 (C-14, t), 52.2 (C-9, d), 109.5 (C-16, t), 121.2 (C-7, d), 135.9 (C-8, s), 150.5 (C-15, d), 185.3 (C-18, s).

4.3.8. Kayadiol (8)

Colorless prisms; $[\alpha]_D^{20} = +43.8$ (c 1.4, CHCl₃); mp: 112 °C; ¹H NMR (600 MHz, CDCl₃) δ 0.69 (3H, s, H-20), 0.72 (3H, s, H-19), 1.64 (3H, s, H-16), 0.98–1.80 (15H, m), 1.97–2.12 (2H, m), 2.35 (1H, m, H-9), 3.07 (1H, d, $J = 10.3$ Hz, H-18 α), 3.40 (1H, d, $J = 10.9$ Hz, H-18 β), 4.13 (2H, d, $J = 6.8$ Hz, H-15), 4.49 (1H, s, H-17 β), 4.81 (1H, s, H-17 α), 5.35 (1H, t, $J = 6.1$ Hz, H-14); ¹³C NMR (150 MHz, CDCl₃) δ 15.5 (C-20, q), 16.5 (C-16, q), 17.8 (C-2, t), 18.8 (C-11, t), 21.9 (C-6, t), 24.3 (C-19, q), 35.6 (C-3, t), 38.1 (C-1, t), 38.2 (C-12, t), 38.5 (C-10, s), 38.7 (C-7, t), 39.7 (C-4, s), 48.6 (C-5, d), 56.4 (C-9, d), 59.6 (C-15, t), 72.2 (C-18, t), 106.6 (C-17, t), 123.2 (C-14, d), 140.7 (C-13, s), 148.5 (C-8, s).

4.3.9. Amentoflavone (9)

Pale yellow amorphous powder; mp: 230 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 6.18 (1H, d, $J = 2.0$ Hz, H-6), 6.37 (1H, s, H-6''), 6.45 (1H, d, $J = 2.0$ Hz, H-8), 6.70 (2H, s, H-3, 3''), 6.80 (2H, s, H-3''', 5'''), 7.12 (1H, d, $J = 8.6$ Hz, H-5'), 7.58 (2H, s, H-2''', 6'''), 8.00 (1H, dd, $J = 2.3$, 8.6 Hz, H-6'), 8.02 (1H, d, $J = 2.3$ Hz, H-2'); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 94.0 (C-6'', d), 98.8 (C-6, 8, d), 102.6 (C-3'', d), 102.9 (C-4a, s), 103.5 (C-3, d), 103.7 (C-8'', s), 104.2 (C-4a'', s), 115.7 (C-3''', 5'', d), 116.4 (C-5', d), 120.3 (C-1''', s), 120.7 (C-1', s), 121.4 (C-3', s), 127.7 (C-6', d), 128.2 (C-2''', 6''', d), 131.4 (C-2', d), 154.5 (C-8a'', s), 157.4 (C-8a, s), 160.0 (C-5'', s),

160.5 (C-5, s), 160.9 (C-4', s), 161.4 (C-7'', s), 162.7 (C-4''', s), 163.6 (C-2, s), 163.8 (C-2'', s), 164.1 (C-7, s), 181.7 (C-4'', s), 182.1 (C-4, s).

4.3.10. Bilobetin (10)

Pale yellow amorphous powder; mp: 225 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 3.78 (OMe), 6.18 (1H, d, $J = 1.8$ Hz, H-6), 6.37 (1H, s, H-6''), 6.47 (1H, s, H-8), 6.71 (2H, d, $J = 8.7$ Hz, H-3''', 5'''), 6.78 (1H, s, H-3''), 6.91 (1H, s, H-3), 7.33 (1H, d, $J = 9.2$ Hz, H-5'), 7.50 (2H, d, $J = 9.2$ Hz, H-2''', 6'''), 8.06 (1H, d, $J = 2.3$ Hz, H-2'), 8.16 (1H, m, H-6'); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 55.8 (OMe), 94.1 (C-8, d), 98.7 (C-6, d), 98.9 (C-6'', d), 102.4 (C-3, 3'', d), 103.4 (C-4a'', s), 103.6 (C-8'', 4a, s), 111.6 (C-5', d), 115.7 (C-3''', 5''', d), 121.2 (C-1''', s), 121.6 (C-3', s), 122.4 (C-1', s), 127.9 (C-2', d), 128.1 (C-2''', 6''', d), 130.9 (C-6', d), 154.3 (C-8a'', s), 157.4 (C-8a, s), 160.4 (C-5'', s), 160.6 (C-4', s), 161.1 (C-4''', s), 161.4 (C-5, s), 162.6 (C-7'', s), 163.1 (C-2, s), 163.3 (C-7, s), 164.3 (C-2'', s), 181.7 (C-4'', s), 182.0 (C-4, s).

4.3.11. Ginkgetin (11)

Pale yellow amorphous powder; mp: 235 °C; ¹H NMR (400 MHz, acetone-*d*₆) δ 5.74 (1H, d, $J = 1.9$ Hz, H-6), 5.96 (1H, s, H-6''), 6.03 (1H, d, $J = 1.9$ Hz, H-8), 6.46 (2H, H-3''', 5'''), 6.47 (1H, s, H-3''), 6.48 (1H, s, H-3), 6.89 (1H, d, $J = 8.8$ Hz, H-5'), 7.16 (2H, H-2''', 6'''), 7.61 (1H, d, $J = 2.4$ Hz, H-2'), 7.73 (1H, dd, $J = 2.4$, 9.2 Hz, H-6'); ¹³C NMR (100 MHz, acetone-*d*₆) δ 55.9 (OMe), 56.4 (OMe), 94.9 (C-8, d), 99.7 (C-6, d), 99.8 (C-6'', d), 104.2 (C-3, 3'', d), 104.4 (C-4a'', s), 104.8 (C-8'', s), 105.5 (C-4a, s), 111.5 (C-5', d), 115.4 (C-3''', 5''', d), 116.8 (C-1''', s), 117.5 (C-3', s), 122.8 (C-1', s), 124.3 (C-2', d), 128.8 (C-2''', 6''', d), 132.2 (C-6', d), 154.3 (C-8a'', s), 158.9 (C-8a, s), 160.4 (C-5'', s), 162.0 (C-7'', s), 162.1 (C-4', s), 162.3 (C-4''', s), 163.0 (C-5, s), 163.5 (C-2, s), 163.6 (C-2'', s), 165.0 (C-7, s), 183.1 (C-4'', s), 183.4 (C-4, s).

4.3.12. Sciadopitysin (12)

Pale yellow amorphous powder; mp: 273 °C; ¹H NMR (500 MHz, methanol-*d*₃) δ 6.18 (1H, d, $J = 2.1$ Hz, H-6), 6.46 (1H, d, $J = 2.1$ Hz, H-8), 6.66 (1H, s, H-6''), 6.90 (2H, H-3, 3''), 6.93 (2H, H-3''', 5'''), 7.35 (1H, d, $J = 8.8$ Hz, H-5'), 7.61 (2H, d, $J = 8.8$ Hz, H-2''', 6'''), 8.05 (1H, d, $J = 2.3$ Hz, H-2'), 8.17 (1H, dd, $J = 2.6$, 8.5 Hz, H-6'); ¹³C NMR (125 MHz, methanol-*d*₃) δ 55.5 (OMe), 55.9 (OMe), 56.5 (OMe), 94.1 (C-8, d), 95.5 (C-6, d), 98.9 (C-6'', d), 103.2 (C-3'', d), 103.7 (C-4a'', s), 103.8 (C-3, d), 104.1 (C-8'', s), 104.6 (C-4a, s), 111.8 (C-5', d), 114.5 (C-3''', 5''', d), 121.2 (C-3', s), 122.6 (C-1', s), 122.7 (C-1''', s), 127.9 (C-2''', 6''', d), 128.3 (C-2', d), 153.4 (C-6', d), 157.4 (C-8a'', s), 160.3 (C-8a, s), 161.4 (C-4', s), 161.5 (C-5, s), 162.3 (C-4''', s), 162.6 (C-7'', s), 163.1 (C-2, s), 163.4 (C-2'', s), 164.3 (C-7, s), 181.7 (C-4'', s), 182.3 (C-4, s).

4.4. SARS 3C-like protease (3CL^{Pro}) inhibition assay

The inhibitory effect of ethanol extract compounds on SARS-CoV 3CL^{Pro} (Lifesensors Co., USA) was measured using a FRET method developed by us as described previously.¹⁴ In this assay, the fluorogenic peptide Dabcyl-KNSTLQSGLRKE-Edans (Anygen Co., Republic of Korea) is used as a substrate, and the enhanced fluorescence due to substrate cleavage is measured at 360/40 nm and recorded as relative fluorescence units (RFUs). The IC₅₀ value of individual compounds was measured in a reaction mixture containing 10 μ g/mL of the 3CL^{Pro} (final concentration, 2.5 μ g) and 10 μ M fluorogenic 14-mer peptide substrate in 20 mM Bis-Tris buffer. Reactions were run for 60 min at room temperature with continuous monitoring of fluorescence with a FLx 800 (BioTeck Instrument Inc., USA). The inhibition ratio was calculated using the equation:

$$\text{Activity (\%)} = [(S - S_0)/(C - C_0)] \times 100 \quad (1)$$

where C is the fluorescence of the control (enzyme, buffer, and substrate) after 60 min of incubation, C_0 is the fluorescence of the control at zero time, S is the fluorescence of the tested samples (enzyme, sample solution, and substrate) after incubation, and S_0 is the fluorescence of the tested samples at zero time. To allow for the quenching effect of the samples, the sample solution was added to the reaction mixture C , and any reductions in fluorescence were assessed. Kinetic parameters were obtained using various concentrations of FRET peptide in the fluorescent assay. The maximal velocity ($V_{\max} = 44.4 \pm 6.2$ intensity min^{-1}), Michaelis-Menten constant ($K_m = 9.7 \pm 0.2 \mu\text{M}$), and inhibition constant (K_i) were calculated from the Lineweaver-Burk and Dixon plots.

4.5. Molecular docking study of SARS-CoV 3CL^{pro} with selected inhibitors

Molecular docking with SARS-CoV 3CL^{pro} was simulated and analyzed using Autodock 3.0.5 software.²⁵ The SARS-CoV 3CL^{pro} Crystal structure [PDB code 2Z3E with inhibitor KCQ, (3S)-3-[(2S)-2-amino-3-oxyobutyl]pyrrolidin-2-one] at 2.3 Å was prepared for docking and post-docking refinement.²⁵ For docking experiment of each biflavone with 2Z3E, all water molecules and the inhibitor (KCQ) located in the active site of 2Z3E were removed, and the structure information containing only the amino acid residues of the 3CL^{pro} enzyme was used. AutoDockTools software was used for the addition of polar hydrogen atoms to the macromolecule to correct calculation of partial atomic charges. Aspartic and glutamic acids were deprotonated, lysine and arginine were protonated, and histidine was neutral. Kollman charges were assigned for all atoms. Three dimensional affinity grid size with $60 \times 60 \times 60$ on active size with 0.375 Å spacing was calculated for each atom type by using of AutoGrid 3. The docking parameters for Lamarckian genetic algorithm between 3CL^{pro} with different biflavones were as follows: population size of 250 individuals, random starting position and conformation, translation step ranges of 2.0 Å, maximum of 10,000,000 energy evaluations, number of top individuals to survive to next generation 1, maximum of generations 27,000, mutation rate of 0.02, rate of crossover 0.8, local search rate 0.06, 50 docking runs. The maximum number of iteration per local search was set to 300. Each docking job produced 50 docked conformations. Binding energy between the three-dimensional structure of SARS-CoV 3CL^{pro} and biflavones was then calculated. The docking results were ranked according to docking energy scores.

4.6. HPLC apparatus and chromatographic conditions

The extracts (5 mg/mL) and fractions (5 mg/mL) were passed through 0.45- μm filters (Millipore, MSI, Westboro, MA, USA) before chromatographic separation using an Agilent 1200 HPLC system (Agilent Technologies, Palo Alto, CA, USA) equipped with a quaternary HPLC pump, degasser, autosampler and UV detector (VWD). The mobile phase for HPLC consisted of water (solvent A) and acetonitrile (solvent B). The solvent gradient was as follows (starting with 100% solvent A): 0 min, 0% B; 10 min, 30% B; 20 min, 60% B; 30 min, 100% B; 35 min, 100% B. The flow rate was 0.5 mL/min, the injection volume was 10 μL and eluent was detected at 210 nm. All HPLC analyses were performed at 30 °C.

Acknowledgments

This research was supported by National Research Foundation grant funded by Korea government (MEST) (No. 2010-0002047) and KRIBB Research Initiative Program, Republic of Korea. Molecular docking study was partly supported by the EU Framework Program (EU-FP) (Grant No. 2009-50283).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bmc.2010.09.035.

References and notes

- Berger, A.; Drosten, C.; Doerr, H. W.; Sturmer, M.; Preiser, W. *J. Clin. Virol.* **2004**, 29, 13.
- Stadler, K.; Massignani, V.; Eickmann, M.; Becker, S.; Abrignani, S.; Klenk, H. D.; Rappuoli, R. *Nat. Rev. Microbiol.* **2003**, 1, 209.
- Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H. R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R. A.; Berger, A.; Burguiere, A. M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J. C.; Muller, S.; Rickerts, V.; Sturmer, M.; Vieth, S.; Klenk, H. D.; Osterhaus, A. D.; Schmitz, H.; Doerr, H. W. *N. Eng. J. Med.* **2003**, 348, 1967.
- Peiris, J. S.; Lai, S. T.; Poon, L. L.; Guan, Y.; Yam, L. Y.; Lim, W.; Nicholls, J.; Yee, W. K.; Yan, W. W.; Cheung, M. T.; Cheng, V. C.; Chan, K. H.; Tsang, D. N.; Yung, R. W.; Ng, T. K.; Yuen, K. Y. *Lancet* **2003**, 361, 1319.
- Rota, P. A.; Oberste, M. S.; Nix, W. A.; Campagnoli, R.; Icenogle, J. P.; Penaranda, S.; Bankamp, B.; Maher, K.; Chen, M.-H.; Tong, S.; Tamin, A.; Lowe, L.; Frace, M.; De Risi, J. L.; Chen, Q.; Wang, D.; Erdman, D. D.; Peret, T. C. T.; Burns, C.; Ksiazek, T. G.; Rollin, P. E.; Sanchez, A.; Liffick, S.; Holloway, B.; Limor, J.; McCaustland, K.; Olsen-Rasmussen, M.; Fouchier, R.; Gunther, S.; Osterhaus, A. D. H. E.; Drosten, C.; Pallansch, M. A.; Anderson, L. J.; Bellini, W. J. *Science* **2003**, 300, 1394.
- Anand, K.; Ziebuhr, J.; Wadhwang, P.; Mesturs, J. R.; Hilgenfeld, R. *Science* **2003**, 300, 1763.
- Cinatl, J., Jr.; Michaelis, M.; Hoever, G.; Preiser, W.; Doerr, H. W. *Antiviral Res.* **2005**, 66, 81.
- Wu, C.-Y.; Jan, J.-T.; Ma, H.-H.; Kuo, C.-J.; Juan, H.-F.; Cheng, Y.-S. E.; Hsu, H.-H.; Huang, H.-C.; Wu, D.; Brik, A.; Liang, F.-S.; Liu, R.-S.; Fang, J.-M.; Chen, S.-T.; Liang, P.-H.; Wong, C.-H. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, 101, 10012.
- Kao, R. Y.; Tsui, W. H. W.; Lee, T. S. W.; Tanner, J. A.; Watt, R. M.; Huang, J.-D.; Hu, L.; Chen, G.; Chen, Z.; Zhang, L.; He, T.; Chan, K.-H.; Tse, H.; To, A. P. C.; Ng, L. W. Y.; Wong, B. C. W.; Tsoi, H.-W.; Yang, D.; Ho, D. D.; Yuen, K.-Y. *Chem. Biol.* **2004**, 11, 1293.
- Chen, L.-R.; Wang, Y.-C.; Lin, Y.-W.; Chou, S.-Y.; Chen, S.-F.; Liu, L.-T.; Wu, Y.-T.; Kuo, C.-J.; Chen, T. S.-S.; Juang, S.-H. *Bioorg. Med. Chem. Lett.* **2005**, 15, 3058.
- Shie, J.-J.; Fang, J.-M.; Kuo, T.-H.; Kuo, C.-J.; Liang, P.-H.; Huang, H.-J.; Yang, W.-B.; Lin, C.-H.; Chen, J.-L.; Wu, Y.-T.; Wong, C.-H. *J. Med. Chem.* **2005**, 48, 4469.
- Wen, C.-C.; Kuo, Y.-H.; Jan, J.-T.; Liang, P.-H.; Wang, S.-Y.; Liu, H.-G.; Lee, C.-K.; Chang, S.-T.; Kuo, C.-J.; Lee, S.-S.; Hou, C.-C.; Hsiao, P.-W.; Chien, S.-C.; Shyur, L.-F.; Yang, N.-S. *J. Med. Chem.* **2007**, 50, 4087.
- Lin, C.-W.; Tsai, F.-J.; Tsai, C.-H.; Lai, C.-C.; Wan, L.; Ho, T.-Y.; Hsieh, C.-C.; Chao, P.-D. *Antiviral Res.* **2005**, 68, 36.
- Ryu, Y. B.; Park, S.-J.; Kim, Y. M.; Lee, J.-Y.; Seo, W. D.; Chang, J. S.; Park, K. H.; Rho, M.-C.; Lee, W. S. *Bioorg. Med. Chem. Lett.* **2010**, 20, 1873.
- Harrison, L. J.; Asakawa, Y. *Phytochemistry* **1987**, 26, 1211.
- Yang, J.-W.; Orihara, Y. *Tetrahedron* **2002**, 58, 1265.
- Wang, S.-Y.; Wu, J.-H.; Shyur, L.-F.; Kuo, Y.-H.; Chang, S.-T. *Holzforchung* **2002**, 56, 487.
- Son, K.-H.; Oh, H.-M.; Choi, S.-K.; Han, D. C.; Kwon, B.-M. *Bioorg. Med. Chem. Lett.* **2005**, 15, 2019.
- Matsumoto, T.; Imai, S.; Ondo, K.; Takeyama, N.; Kataoka, H.; Yamamoto, Y.; Fukui, K. *Bull. Chem. Soc. Jpn.* **1982**, 55, 891.
- Antkowiak, W.; Apsimon, J. W.; Edwards, O. E. *J. Org. Chem.* **1962**, 27, 1930.
- Miura, H.; Kihara, T.; Kawano, N. *Chem. Pharm. Bull.* **1969**, 17, 150.
- Li, S.-H.; Zhang, H.-J.; Niu, X.-M.; Yao, P.; Sun, H.-D.; Fong, H. S. S. *J. Nat. Prod.* **2003**, 66, 1002.
- Hanrahan, J. R.; Chebib, M.; Davucheron, N. L. M.; Hall, B. J.; Johnston, G. A. R. *Bioorg. Med. Chem. Lett.* **2003**, 13, 2281.
- Yin, J.; Niu, C.; Cherney, M. M.; Zhang, J.; Huitema, C.; Eltis, L. D.; Vederas, J. C.; James, M. N. J. *Mol. Biol.* **2007**, 371, 1060.
- Kasam, V. Z. M.; Maass, A.; Schwichtenberg, H.; Wolf, A.; Jacq, N.; Breton, V.; Hofmann-Apitius, M. *J. Chem. Inf. Med. Chem.* **2007**, 47, 1818.